BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37414853)

  • 1. Features of metabolism associated molecular patterns in pancreatic ductal adenocarcinoma.
    Chen J; Wang Y; Jiang H
    Cancer Gene Ther; 2023 Sep; 30(9):1296-1307. PubMed ID: 37414853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
    Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
    Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
    Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
    Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
    Nimmakayala RK; Leon F; Rachagani S; Rauth S; Nallasamy P; Marimuthu S; Shailendra GK; Chhonker YS; Chugh S; Chirravuri R; Gupta R; Mallya K; Prajapati DR; Lele SM; C Caffrey T; L Grem J; Grandgenett PM; Hollingsworth MA; Murry DJ; Batra SK; Ponnusamy MP
    Oncogene; 2021 Jan; 40(1):215-231. PubMed ID: 33110235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
    Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
    Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma.
    Mahajan UM; Alnatsha A; Li Q; Oehrle B; Weiss FU; Sendler M; Distler M; Uhl W; Fahlbusch T; Goni E; Beyer G; Chromik A; Bahra M; Klein F; Pilarsky C; Grützmann R; Lerch MM; Lauber K; Christiansen N; Kamlage B; Regel I; Mayerle J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
    Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
    Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
    Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
    Front Immunol; 2021; 12():790661. PubMed ID: 34925373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
    J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin.
    Espinet E; Gu Z; Imbusch CD; Giese NA; Büscher M; Safavi M; Weisenburger S; Klein C; Vogel V; Falcone M; Insua-Rodríguez J; Reitberger M; Thiel V; Kossi SO; Muckenhuber A; Sarai K; Lee AYL; Backx E; Zarei S; Gaida MM; Rodríguez-Paredes M; Donato E; Yen HY; Eils R; Schlesner M; Pfarr N; Hackert T; Plass C; Brors B; Steiger K; Weichenhan D; Arda HE; Rooman I; Kopp JL; Strobel O; Weichert W; Sprick MR; Trumpp A
    Cancer Discov; 2021 Mar; 11(3):638-659. PubMed ID: 33060108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
    Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
    Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
    BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
    Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
    J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Ductal Epithelial Cells.
    Otto L; Rahn S; Daunke T; Walter F; Winter E; Möller JL; Rose-John S; Wesch D; Schäfer H; Sebens S
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.